Loading
FORT MYERS — Clinical lab firm NeoGenomics says it's validated and launched the first two of a series of next-generation cancer profiling tests.
The company, which specializes in cancer genetics testing, says it's the first in the industry to offer plasma-based next-generation sequencing tests designed for profiling myelodysplastic syndrome (MDS) and solid tumor cancers. Additional cancer-type specific next generation tests are currently being validated, according to a release, and are scheduled for launch over the next several months.
The MDS next-generation sequencing test can be performed on bone marrow, peripheral blood and plasma samples, the company says. The test is particularly important for confirming an MDS diagnosis, which can be hard to detect in early stages of the disease.
The solid tumor cancer-profiling test covers 48 genes and is performed on paraffin-embedded tissue.
“NeoGenomics is committed to developing and using cutting edge technology to provide efficient and reliable clinical tests,” Chairman and CEO Doug VanOort says in the release. “We believe that targeted next generation sequencing technology has advanced sufficiently to be offered more routinely in high-throughput clinical laboratory testing for cancer patients.”
Fort Myers-based NeoGenomics has labs in Tampa, Fort Myers, Nashville and Irvine, Calif. Clients include pathologists, oncologists, urologists and other clinicians, in addition to hospitals nationwide. The publicly traded company (symbol: NEO; recent price: $3.45) earned $857,000 on revenues of $18.3 million in the 2013 fourth quarter. That was up from a loss of $113,000 on revenues of $14.9 million in the same quarter in 2012.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
